Table 1 Baseline demographic and exposure profile of participants initially classified as Chronic Beryllium Disease (CBD) and Beryllium Sensitization (BeS), with and without those with COPD
From: Long-term follow-up of beryllium sensitized workers from a single employer
| Â | BeS COPD in (n = 50) | CBD COPD in (n = 22) | P value | BeS COPD out (n = 40) | CBD COPD out (n = 20) | P value |
|---|---|---|---|---|---|---|
Age in years (s.d.) | 44.2 (11.1) | 47.8 (10.5) | 0.20 | 42.6 (11.2) | 46.7 (10.2) | 0.17 |
Sex (%male) | 78 | 77 | 0.95 | 73 | 80 | 0.53 |
Race (% white) | 94 | 100 | 0.71 | 93 | 100 | 0.66 |
Smoking Status | Â | Â | Â | Â | Â | Â |
Non-smoker% | 42 | 36 | Â | 50 | 40 | Â |
Ex smoker % | 20 | 36 | 0.32 | 18 | 40 | 0.16 |
Current smoker % | 38 | 27 | Â | 33 | 20 | Â |
Mean length from hire date to baseline evaluation in years (s.d) | 12.4 (11.1) | 13.7 (7.0) | 0.60 | 11.6 (10.1) | 14.3 (7.0) | 0.28 |
Period of beryllium exposure in years (s.d) | 15.6 (11.8) | 18.0 (8.4) | 0.41 | 15.1 (11.7) | 18.7 (8.5) | 0.22 |
Time from baseline to follow-up evaluation(s.d) | 7.1 (3.0) | 8.1 (3.4) | 0.20 | 7.0 (3.0) | 8.5 (3.4) | 0.09 |
History of hay fever, asthma or eczema (% positive) | 48 | 50 | 0.96 | 50 | 45 | 0.72 |
Pulmonary Function Tests | Â | Â | Â | Â | Â | Â |
FEV1 mean % predicted (s.d.) | 89.3 (14.5) | 86.2 (16.7) | 0.43 | 92.6 (12.7) | 89.1 (14.3) | 0.33 |
FVC mean % predicted (s.d.) | 96.1 (14.8) | 88.8 (11.7) | 0.04 | 97.9 (14.3) | 89.6 (11.5) | 0.03 |
FEV1/FVC mean % predicted (s.d) | 92.8 (10.3) | 95.0 (12.0) | 0.44 | 95.6 (8.1) | 97.0 (8.1) | 0.52 |
DLCO mean % predicted (s.d.) | 101.3 (16.1) | 99.9 (23) | 0.77 | 103.6 (14.2) | 104.0 (20.1) | 0.94 |
TLC mean %(predicted) (s.d.) | 98.6 (14.6) | 94.5 (14.5) | 0.35 | 98.6 (14.3) | 91.5 (12.0) | 0.10 |
Clinical evidence of COPD N (%) | 10 (20) | 2 (9.1) | 0.32 | Â | Â | Â |